Search

Displaying results 2261 - 2270 of 8573 in total
  1. Drug

    Bismuth subcitrate potassium

    go.drugbank.com/drugs/DB09275
    ApprovedInvestigational

    A bismuth compound used for peptic ulcer and gastro-oesophageal reflux disease (GORD).

  2. Drug

    Edetate calcium disodium anhydrous

    go.drugbank.com/drugs/DB14598
    ApprovedInvestigational

    [A204173] Edetate calcium disodium was granted FDA approval on 16 July 1953.[L12774]

    Products: Calcium Disodium Versenate Liq 200mg/ml
  3. Drug

    Necitumumab

    go.drugbank.com/drugs/DB09559
    ApprovedInvestigationalWithdrawn

    Necitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist. … Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC).

    Products: PORTRAZZA CONCENTRATE FOR SOLUTION FOR INFUSION 800MG/50ML
  4. Drug

    Prucalopride

    go.drugbank.com/drugs/DB06480
    ApprovedInvestigational

    [A37348] The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. … [A40254] Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009,[A40250] in Canada on December 7, 2011 and by the FDA on December 17, 2018.[L4880]

  5. Drug

    Peramivir

    go.drugbank.com/drugs/DB06614
    ApprovedInvestigational

    The development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic. … Due to the poor oral bioavailability, the oral formulation of the drug was previously abandoned by Johnson and Johnson Company.

  6. Drug

    Eplontersen

    go.drugbank.com/drugs/DB16199
    ApprovedInvestigational

    It was previously investigated as a potential treatment for hereditary transthyretin-mediated amyloidosis. … [A262985] As eplontersen targets both the WT and mutant TTR, it poses tremendous promises as a treatment.

  7. Drug

    Aceclidine

    go.drugbank.com/drugs/DB13262
    Approved

    [A274283] As compared to less selective miotics, like [pilocarpine], aceclidine's relative stimulation of the ciliary muscle is significantly less and, as such, induces far less myopic shift, lens thickening … [A274278] Aceclidine was approved the US FDA in July 2025 for the treatment of adult patients with presbyopia.[L53768]

  8. Drug

    Sulopenem etzadroxil

    go.drugbank.com/drugs/DB16335
    ApprovedInvestigational

    [L51768] Sulopenem etzadroxil was approved by the FDA in October 2024 for the treatment of uncomplicated urinary tract infections.

  9. Drug

    Dextroamphetamine

    go.drugbank.com/drugs/DB01576
    ApprovedIllicitInvestigational

    Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder.[L6010,L52145]

  10. Drug

    Umifenovir

    go.drugbank.com/drugs/DB13609
    Investigational

    [A191475] It has been in use in Russia for approximately 25 years and in China since 2006. … [A191475,A191412] This dual activity may also confer additional protection against viral resistance, as the development of resistance to umifenovir does not appear to be significant.